The U.S. Food and Drug Administration (FDA) has granted clearance to UltraSight to expand its Echo Stewardship Platform to support compatibility with additional ultrasound system types.
The expanded authorization allows AI-guided focused cardiac ultrasound (FoCUS) to be used across more devices, including handheld, laptop, and cart-based systems. This will allow healthcare providers to scale FoCUS across compatible ultrasound equipment they already own, UltraSight noted.
UltraSight's Echo Stewardship Program is designed to expand the effective imaging workforce while preserving qualified physician oversight for final interpretation and reporting, according to UltraSight. The program enables trained clinicians, including nonsonographer providers such as advanced practice providers (APPs), to acquire diagnostic-quality FoCUS exams under physician oversight, the firm said.
UltraSight added that it will assist health systems and device partners throughout 2026 to bring expanded multidevice compatibility online and integrate the platform into cardiology, acute care, and outpatient workflows.
